title: Lower birth weight as a critical effect of chlorpyrifos: a comparison of human and animal data.
abstract: Chlorpyrifos is an irreversible inhibitor of cholinesterase (ChE), and inhibition of ChE is believed to be the most sensitive effect in all animal species evaluated and in humans. Recent epidemiology studies reported associations between umbilical cord plasma chlorpyrifos levels and fetal birth weight decreases among minority women living in New York City during pregnancy. These associations raise questions whether impaired fetal development is the critical effect rather than the inhibition of ChE as is currently believed so. We analyze the available information from epidemiology studies and animal studies in order to identify the relative sensitivity of decreased birth weight and inhibition of ChE from exposure to chlorpyrifos. We find that the positive associations from some epidemiology studies are different from other epidemiology investigations. Moreover, a direct comparison of experimental animal neonatal information shows that cholinesterase inhibition is a more sensitive indicator of adverse effect than reduced body weight, and that neonates are equally, or perhaps less sensitive to cholinesterase inhibition than their maternal parent. Based on a review of human studies and comparison of human cord blood chlorpyrifos concentrations with blood chlorpyrifos concentrations that in animals caused effects with good dose-response, it appears unlikely that the exposure level encountered by the population reported in [Whyatt, R.M., Rauh, V., Barr, D.B., Camann, D.E., Andrews, H.F., Garfinkel, R., Hoepner, L.A., Diaz, D., Dietrich, J., Reyes, A., Tang, D., Kinney, P.L., Perera, F.P., 2004. Prenatal insecticide exposures and birth weight and length among an urban minority cohort. Environ. Health Perspect. 112, 1125-1132.] study would cause any fetal developmental effect. Moreover, the critical effect for chlorpyrifos still appears to be cholinesterase inhibition.
authors.affiliation: Toxicology Excellence for Risk Assessment (TERA), 2300 Montana Ave., Suite 409, Cincinnati, OH 45211, USA.
authors.forename: Qiyu
authors.initials: Q
authors.lastname: Zhao
authors.forename: Bernard
authors.initials: B
authors.lastname: Gadagbui
authors.forename: Michael
authors.initials: M
authors.lastname: Dourson
mesh_terms: D000818:Animals; D004390:Chlorpyrifos / Q000009:adverse effects* / Q000097:blood; D002800:Cholinesterase Inhibitors / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight / Q000097:blood / Q000254:growth & development* / Q000502:physiology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects
chemical_list: D002800:Cholinesterase Inhibitors; D004390:Chlorpyrifos